Aktualnie znajdujesz się na:

Non-commercial clinical trial of CAR-T therapy with Medical Research Agency funding

Medical Research Agency has signed a contract for the implementation of the project called "Polish Chimeric Antigen Receptor T-cell Network", thanks to which patients in Poland will have access to the most modern treatment methods.

CAR-T cell therapy is the most advanced and personalized technology used in the treatment of hematooncology, which involves creating a drug for each patient based on their own lymphocytes. The use of the immune system to fight cancer consists in taking T lymphocytes from the patient, which are then genetically modified in the laboratory. This gene encodes the production by T lymphocyte of a receptor recognising specific antigens of cancer cells. CAR-T cell therapy can achieve complete remission in approx. 90 percent. patients with acute lymphoblastic leukemia,

The project will be implemented by a consortium consisting of:

  1. Medical University of Warsaw - leader of the consortium
  2. Pomeranian Medical University in Szczecin,
  3. Medical University of Lodz.
  4. National Institute of Oncology im. Maria Skłodowska Curie
  5. Hospital, University Clinical Center of Warsaw Medical
  6. University, Institute of Hematology and Transfusiology,
  7. Transfiguration Clinical Hospital of Maria Skłodowska Curie Medical University,
  8. Warsaw Medical University. The University Hospital No. 1 in Poznan, the University Hospital No. 1 in Poznan, 
  9. University Hospital No. 2 in Poznan. Dr. Antoni Jurasz in Bydgoszcz.

We have allocated PLN 100 million for the project.


go up